Market Overview:
The global Alimta market is expected to grow at a CAGR of 5.5% during the forecast period from 2018 to 2030. The growth in the market can be attributed to factors such as rising incidence of cancer, increasing demand for targeted therapies, and growing awareness about cancer treatments. Based on type, the global Alimta market is segmented into 100mg and 500mg. The 100mg segment is expected to account for a larger share of the market than the 500mg segment during the forecast period. This can be attributed to its lower price point and higher availability as compared to 500mg Alimta tablets. Based on application, the global Alimta market is divided into pleural mesothelioma and non-small cell lung cancer (NSCLC). NSCLC accounts for a larger share of the global Alimta market than pleural mesothelioma due to its high prevalence rate across all regions studied in this research study.
Product Definition:
Alimta is a chemotherapy drug used to treat lung cancer. It is important because it can extend the life of someone with the disease.
100mg:
100mg is used to treat heart failure and certain types of hypertension. It's an angiotensin II receptor blocker, which works by decreasing the blood pressure through a decrease in the volume of blood that flows through the arteries.
It has been found to be more effective than conventional antihypertensive drugs such as diuretics and beta-blockers for treating high blood pressure, without causing any additional risks associated with kidney or liver damage.
500mg:
500mg is used in Alimta for the treatment of atrial fibrillation, which is a type of cardiac arrhythmia. It works by slowing down the heart rate to reduce the amount of blood pumped out with each beat. This reduces the risk of blood clotting and increases your chances for survival.
Application Insights:
Pleural mesothelioma application segment led the global market in 2017. This is attributed to high incidence rates of asbestosis and exposure to asbestos fibers during the course of mining activities in various countries such as Turkey, South Africa, Australia and New Zealand. As per the data published by Asbestos Diseases Association (ADA), more than 15,000 people are diagnosed with pleural mesothelioma each year globally.
Non-small cell lung cancer application segment is expected to witness lucrative growth over the forecast period due to increasing cases of smoking across all age groups globally including children which leads to increased risk for developing this type of cancer.
Regional Analysis:
North America dominated the global alimta market in terms of revenue with a share of over 57.0% in 2017. This is attributed to the high incidence rate of NSCLC and pleural mesothelioma, rising awareness about cancer treatment options, availability of highly effective drugs, and supportive healthcare system in this region. The U.S.
Growth Factors:
- Increasing incidence of lung cancer: The incidence of lung cancer is increasing globally due to the increase in the number of smokers, and this is expected to drive the demand for Alimta.
- Growing awareness about Alimta: There is growing awareness about the benefits of Alimta among physicians and patients, which is likely to boost its demand in the coming years.
- Launch of new indications: Eli Lilly has been launching new indications for Alimta, such as non-small cell lung cancer (NSCLC) and mesothelioma, which will help fuel its growth in the future.
- Availability of reimbursement: The availability of reimbursement for Alimta from various insurance providers is likely to boost its adoption among patients worldwide.
Scope Of The Report
Report Attributes
Report Details
Report Title
Alimta Market Research Report
By Type
100mg, 500mg
By Application
Pleural Mesothelioma, Non-small Cell Lung Cancer
By Companies
Eli Lilly, Abbott Healthcare, Cadila Healthcare, Eagle Pharmaceuticals
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
149
Number of Tables & Figures
105
Customization Available
Yes, the report can be customized as per your need.
Global Alimta Market Report Segments:
The global Alimta market is segmented on the basis of:
Types
100mg, 500mg
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Pleural Mesothelioma, Non-small Cell Lung Cancer
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Eli Lilly
- Abbott Healthcare
- Cadila Healthcare
- Eagle Pharmaceuticals
Highlights of The Alimta Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- 100mg
- 500mg
- By Application:
- Pleural Mesothelioma
- Non-small Cell Lung Cancer
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Alimta Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Alimta is a medication used to treat patients with advanced cancer. Alimta works by blocking the growth of cancer cells.
Some of the key players operating in the alimta market are Eli Lilly, Abbott Healthcare, Cadila Healthcare, Eagle Pharmaceuticals.
The alimta market is expected to grow at a compound annual growth rate of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Alimta Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Alimta Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Alimta Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Alimta Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Alimta Market Size & Forecast, 2020-2028
4.5.1 Alimta Market Size and Y-o-Y Growth
4.5.2 Alimta Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 100mg
5.2.2 500mg
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Pleural Mesothelioma
6.2.2 Non-small Cell Lung Cancer
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Alimta Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Alimta Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 100mg
9.6.2 500mg
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Pleural Mesothelioma
9.10.2 Non-small Cell Lung Cancer
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 100mg
10.6.2 500mg
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Pleural Mesothelioma
10.10.2 Non-small Cell Lung Cancer
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 100mg
11.6.2 500mg
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Pleural Mesothelioma
11.10.2 Non-small Cell Lung Cancer
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 100mg
12.6.2 500mg
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Pleural Mesothelioma
12.10.2 Non-small Cell Lung Cancer
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 100mg
13.6.2 500mg
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Pleural Mesothelioma
13.10.2 Non-small Cell Lung Cancer
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Alimta Market: Competitive Dashboard
14.2 Global Alimta Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Eli Lilly
14.3.2 Abbott Healthcare
14.3.3 Cadila Healthcare
14.3.4 Eagle Pharmaceuticals
